Pages that link to "Q73407121"
Jump to navigation
Jump to search
The following pages link to Engagement of the OX-40 receptor in vivo enhances antitumor immunity (Q73407121):
Displaying 50 items.
- Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells (Q24317518) (← links)
- Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization (Q24318411) (← links)
- Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy (Q26772347) (← links)
- The impact of the myeloid response to radiation therapy (Q26851643) (← links)
- Immunotherapy in the treatment of non-small cell lung cancer (Q27000382) (← links)
- Science gone translational: the OX40 agonist story (Q27022436) (← links)
- OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells (Q28188488) (← links)
- Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? (Q28207052) (← links)
- Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression (Q28730751) (← links)
- The use of immunotherapy in the treatment of melanoma (Q33593858) (← links)
- Inhibitors of B7-CD28 costimulation in urologic malignancies (Q33827752) (← links)
- Control of immunity by the TNFR-related molecule OX40 (CD134) (Q33899607) (← links)
- Importance of CD4(+) T helper cell responses in tumor immunity. (Q34038795) (← links)
- Costimulatory wars: the tumor menace (Q34046863) (← links)
- T lymphocyte costimulatory molecules in host defense and immunologic diseases (Q34059260) (← links)
- Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance (Q34111451) (← links)
- Antibody-based immunotherapy for malignant glioma (Q34120472) (← links)
- Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population (Q34368855) (← links)
- OX40 is a potent immune-stimulating target in late-stage cancer patients (Q34381674) (← links)
- OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity (Q34477650) (← links)
- New Immunotherapy Strategies in Breast Cancer (Q34549227) (← links)
- OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines (Q34584957) (← links)
- Spinning molecular immunology into successful immunotherapy (Q34632056) (← links)
- Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation (Q34681491) (← links)
- A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. (Q34682173) (← links)
- Tuning tumor-specific T-cell activation: a matter of costimulation? (Q34726004) (← links)
- Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction (Q34954124) (← links)
- The significance of OX40 and OX40L to T-cell biology and immune disease. (Q34979946) (← links)
- Principles of tumor immunosurveillance and implications for immunotherapy (Q35043113) (← links)
- PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer (Q35107110) (← links)
- OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy (Q35118177) (← links)
- Costimulation of T cells by OX40, 4-1BB, and CD27. (Q35145627) (← links)
- HLA class II antibodies in the treatment of hematologic malignancies (Q35206356) (← links)
- Against the self: dendritic cells versus cancer (Q35219334) (← links)
- Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy (Q35294382) (← links)
- Agonist antibodies to TNFR molecules that costimulate T and NK cells (Q35427446) (← links)
- TNF superfamily protein-protein interactions: feasibility of small- molecule modulation (Q35534271) (← links)
- Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors (Q35580479) (← links)
- Immune checkpoint blockade and interferon-α in melanoma (Q35598991) (← links)
- Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma (Q35651705) (← links)
- OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection (Q35766002) (← links)
- Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. (Q35790354) (← links)
- Immunity, cancer and aging: lessons from mouse models. (Q35806782) (← links)
- Co-stimulation: novel methods for preventing viral-induced lung inflammation (Q35862706) (← links)
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain (Q35946627) (← links)
- Modulation of antitumor responses by dendritic cells (Q35988815) (← links)
- Immunotherapy for melanoma: the good, the bad, and the future (Q36223644) (← links)
- Immunotherapy of cancer in 2012. (Q36243536) (← links)
- Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). (Q36251308) (← links)
- Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype (Q36340873) (← links)